Myriad Genetics (MYGN) Cash from Financing Activities (2009 - 2026)

Myriad Genetics (MYGN) has 18 years of Cash from Financing Activities data on file, last reported at -$3.0 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$3.0 million, down 122.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $47.6 million (up 217.33% YoY), and the FY2025 annual result was $64.2 million, up 967.57% from the prior year.
• Cash from Financing Activities rose to -$3.0 million in Q1 2026 per MYGN's latest filing, from -$8.2 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $121.9 million in Q4 2023 and troughed at -$8.8 million in Q1 2024.
• A 5-year average of $11.7 million and a median of -$2.1 million in 2022 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities surged 5904.76% in 2023, then sank 490.48% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at -$2.1 million in 2022, then surged by 5904.76% to $121.9 million in 2023, then slumped by 98.28% to $2.1 million in 2024, then slumped by 490.48% to -$8.2 million in 2025, then jumped by 63.41% to -$3.0 million in 2026.
• Business Quant data shows MYGN's Cash from Financing Activities at -$3.0 million in Q1 2026, -$8.2 million in Q4 2025, and $56.2 million in Q3 2025.